Chemoimmunotherapy and Radiation in Pancreatic Cancer

NCT01903083 ↗

Phase 1 Completed 10 enrolled Providence Health & Services Eli Lilly and Company · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.

Timeline

Start: 2013-07
Primary completion: 2017-12
Completion: 2017-12

Publications

Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, Solhjem MC, To YY, Greathouse A, Tormoen G, Jutric Z, Young K, Bahjat KS, Gough MJ, Crittenden MR. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer. 2016 Aug 16;4:45. doi: 10.1186/s40425-016-0149-6. eCollection 2016.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Tadalafil	Small molecule	2.5 mg	Oral

Indications

No indication recorded.